Security record · archived quarter
DVAX
Dynavax Technologies Corporation · Healthcare · Drug Manufacturers - Specialty & Generic
11Tracked holders
n/aΔ holders
10.39MShares held
$116.72MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 3.09M | n/a | $34.70M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Renaissance Technologies ✦ | 2.48M | n/a | $27.83M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 1.57M | n/a | $17.61M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Fisher Asset Management ✦ | 1.39M | n/a | $15.60M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 840.88K | n/a | $9.44M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Citadel Advisors ✦ | 331.37K | n/a | $3.72M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 241.90K | n/a | $2.72M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 236.40K | n/a | $2.65M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 100.40K | n/a | $1.13M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Marshall Wace ✦ | 80.30K | n/a | $901,769 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Gotham Asset Management ✦ | 36.44K | n/a | $409,221 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 6 shares, $93 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API